Valeant gets license to brodalumab from AZ; European rights terminated
AstraZeneca PLC licensed Valeant Pharmaceuticals International Inc. exclusive rights--excluding Japan and certain Asian countries--to develop and commercialize brodalumab, a Phase III interleukin-17 receptor antagonist for moderate-to-severe plaque psoriasis and psoriatic arthritis.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.